Symkevi is a medicine used to treat cystic fibrosis in patients aged 6 years and above. Cystic fibrosis is an inherited disease that has severe effects on the lungs, the digestive system and other organs.

2023年6月5日 · 2018年11月2日，Vertex 制药宣布欧盟批准其新型两药复方药物 Symkevi（tezacaftor/ivacaftor），这次批准有助于该药物用于治疗更多的囊性纤维化(CF)患者。 该公司在囊性纤维化领域已成功开发有Kalydeco（ivacaftor）和复方药物Orkambi（lumacaftor/ivacaftor），但后者只能用于45%的 ...

SYMDEKO是tezacaftor和ivacaftor的组合，适用于治疗6岁及以上的F508del突变纯合子或对tezacaftor / ivacaftor有反应的囊性纤维化跨膜电导调节剂（CFTR）基因中至少有一种突变的患者。 (12.1，14) 如患者的基因型是未知时，一个FDA-澄清的CF 突变测试应被用于检测一个CFTR突变的存在接着通过双-向测序当通过为使用突变测试指导推荐证实。 剂量和给药方法. 成年和儿童患者年龄12岁和以上：在早晨一片 (含tezacaftor 100 mg/ivacaftor 150 mg)和傍晚一片 ( …

2018年11月5日 · PMLiVE 于 11 月 2 日报道，Vertex 制药宣布欧盟批准其新型两药复方药物 Symkevi（tezacaftor/ivacaftor），这次批准有助于该药物用于治疗更多的囊性纤维化（CF）患者。 该公司在囊性纤维化领域已成功开发有 Kalydeco（ivacaftor）和复方药物 Orkambi（lumacaftor/ivacaftor），但后者只能用于 45% 的有两种拷贝 F508del 突变的患者。 这次批准的新复方药物显示对更多的患者有效，该公司表示，世界上大多数的囊性纤维化患者将 …

6 天之前 · Symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR ...

What is Symkevi and what is it used for? Symkevi is a medicine used to treat cystic fibrosis in patients aged 6 years and above. Cystic fibrosis is an inherited disease that has severe effects on the lungs, the digestive system and other organs. Cystic fibrosis affects the cells that produce mucus and digestive juices.

Symkevi is indicated in a combination regimen with ivacaftor tablet s for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for the F508del mutation

2025年1月7日 · Symkevi Uses, Dosage, Side Effects and more Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals.

Read about Symkevi, which combines ivacaftor with tezacaftor, and find out how the drug could help to treat people with cystic fibrosis (CF).

近日宣布，该公司宣布，欧盟委员会（EC）已批准 Symkevi（tezacaftor/ivacaftor）与Kalydeco（ivacaftor）组合疗法标签扩展，用于治疗6-11岁囊性纤维化（CF）儿童患者， 具体为囊性...